Massicotte-Azarniouch David, Canney Mark, Sood Manish M, Hundemer Gregory L
Department of Medicine, University of Ottawa at The Ottawa Hospital, Ottawa, Ontario, Canada.
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Kidney Int Rep. 2023 Apr 24;8(7):1290-1300. doi: 10.1016/j.ekir.2023.04.016. eCollection 2023 Jul.
The last decade has seen tremendous advances in the prevention and treatment of recurrent hyperkalemia. In this narrative review, we aim to highlight contemporary data on key areas in the epidemiology and management of hyperkalemia. Focusing on drug-induced hyperkalemia (the implications of renin-angiotensin-aldosterone system inhibitors [RAASi] discontinuation and the role of mineralocorticoid receptor antagonists), newer concurrent therapies that modify potassium handling (sodium-glucose transporter 2 inhibitors [SGLT2i]), the introduction of new treatment agents (oral potassium binding agents), and the controversial role of dietary potassium restriction, we apply recent research findings and review the evidence in a case-based format.
在过去十年中,复发性高钾血症的预防和治疗取得了巨大进展。在这篇叙述性综述中,我们旨在强调高钾血症流行病学和管理关键领域的当代数据。聚焦于药物性高钾血症(肾素 - 血管紧张素 - 醛固酮系统抑制剂[RAASi]停药的影响及盐皮质激素受体拮抗剂的作用)、改变钾处理的新型联合疗法(钠 - 葡萄糖协同转运蛋白2抑制剂[SGLT2i])、新治疗药物(口服钾结合剂)的引入以及饮食限钾的争议性作用,我们应用近期研究结果并以基于病例的形式回顾证据。